Association between BMI and colorectal cancer risk
the ONA take:
High pre-diagnosis body mass index (BMI) was associated with increased mortality among patients with colorectal cancer, a new study published in the journal Cancer Epidemiology, Biomarkers & Prevention has shown.
For the study, researchers sought to evaluate the association between BMI and colorectal cancer survival. Researchers analyzed data from 5,615 men and women diagnosed with invasive colorectal cancer who were followed for an average of 5.9 years.
Results showed that high pre-diagnosis BMI was associated with a higher risk of all-cause mortality. The risk of death did not significantly vary by sex, location of cancer, or BRAF mutation status.
According to the National Cancer Institute, previous research has demonstrated that a higher BMI is strongly associated with an increased risk for colorectal cancer among men. A strong association between BMI and waist circumference with colon cancer has been observed in men, with a weaker association observed in women.
High pre-diagnosis body mass index (BMI) was associated with increased mortality among patients with colorectal cancer.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Some Early Breast Cancer Patients Should Have Breast Conservation Instead of Mastectomy
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Targeting AR Mutations Promising in Metastatic Prostate Cancer
- GUCS 2017: Early Immunotherapy Discontinuation in mRCC
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Myalgia-arthralgia Syndrome Associated With Taxanes in Patients with Breast Cancer
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|